Tirzepatide
Zepbound
Sources
fda, as of 2026-09-02Stale
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
ZEPBOUND (tirzepatide) Injection, for subcutaneous use. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, published Sep 2, 2026, Study 1 ITT table
registry, as of 2025-07-24Stale
https://clinicaltrials.gov/study/NCT04184622
Protocol section, NCT04184622 SURMOUNT-1, last update posted 2025-07-24
registry, as of 2026-10-07Stale
https://clinicaltrials.gov/study/NCT05556512
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 15374. Conditions Obesity; Overweight. This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
ClinicalTrials.gov NCT05556512 protocol and results modules
registry, as of 2026-03-19Stale
https://clinicaltrials.gov/study/NCT07481747
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1). Overall status RECRUITING. Phases PHASE3. Lead sponsor Hudson Biotech. Enrollment 2539. Conditions Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes w
ClinicalTrials.gov NCT07481747 protocol and results modules
registry, as of 2024-04-08Stale
https://clinicaltrials.gov/study/NCT04657003
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 938. Conditions Type 2 Diabetes; Overweight; Obesity. This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits). Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline Placebo 30.55 Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline 10 mg Tirzepatide 81.55 Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline 15 mg Tirzepatide 86.41 Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline Placebo 8.68 Percentage of Participants Who Achi
ClinicalTrials.gov NCT04657003 protocol and results modules
registry, as of 2026-05-12Stale
https://clinicaltrials.gov/study/NCT06914895
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 905. Conditions Type 1 Diabetes; Obesity; Overweight. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
ClinicalTrials.gov NCT06914895 protocol and results modules
registry, as of 2024-05-22Stale
https://clinicaltrials.gov/study/NCT04660643
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 783. Conditions Obesity; Overweight. This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which pa Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline Placebo 69.0 Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline Tirzepatide MTD 98.49 Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline Placebo 44.38 Percentage of Participants Who Achieve ≥
ClinicalTrials.gov NCT04660643 protocol and results modules
registry, as of 2025-08-20Stale
https://clinicaltrials.gov/study/NCT04847557
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 731. Conditions Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF). The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity. deaths Tirzepatide - MTD 19 diarrhoea Tirzepatide - MTD 65 nausea Tirzepatide - MTD 62 vomiting Tirzepatide - MTD 38 deaths Placebo 15 diarrhoea Placebo 23 nausea Placebo 23 vomiting Placebo 7
ClinicalTrials.gov NCT04847557 protocol and results modules
registry, as of 2024-05-16Stale
https://clinicaltrials.gov/study/NCT04657016
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 579. Conditions Obesity; Overweight. This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits). Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction Placebo 10.65 Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction Tirzepatide 94.37 Percentage of Participants Who Achieve ≥10%Body Weight Reduction Placebo 4.81 Percentage of Participants Who Achieve ≥10%Body Weight Reduction Tirzepatide 88.03 Percentage of Participants Who Achieve ≥15% Body We
ClinicalTrials.gov NCT04657016 protocol and results modules
registry, as of 2025-04-30Stale
https://clinicaltrials.gov/study/NCT05412004
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 469. Conditions Obstructive Sleep Apnea; Obesity. The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on P deaths Tirzepatide MTD_GPI1 0 diarrhoea Tirzepatide MTD_GPI1 30 nausea Tirzepatide MTD_GPI1 29 vomiting Tirzepatide MTD_GPI1 20 deaths Placebo_GPI1 0 diarrhoea Placebo_GPI1 15 nausea Placebo_GPI1 12 vomiting Placebo_GPI1 5 deaths Tirzepatide MTD_GPI2 0 diarrhoea Tirzepatide MTD_GPI2 26 nausea Tirzepatide MTD_GPI2 26 vomiting Tirzepatide MTD_GPI2 11
ClinicalTrials.gov NCT05412004 protocol and results modules
registry, as of 2026-02-17Stale
https://clinicaltrials.gov/study/NCT06962280
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 465. Conditions Type 1 Diabetes; Obesity; Overweight. The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
ClinicalTrials.gov NCT06962280 protocol and results modules
registry, as of 2026-03-25Stale
https://clinicaltrials.gov/study/NCT06047548
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 441. Conditions Overweight; Obesity. The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
ClinicalTrials.gov NCT06047548 protocol and results modules
registry, as of 2025-04-09Stale
https://clinicaltrials.gov/study/NCT06918405
Efficacy and Safety of Tirzepatide for Weight Management. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Chittagong Medical College. Enrollment 440. Conditions Obesity and Obesity-related Medical Conditions. The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes. The main questions it aims to answer are: Does tirzepatide help people lose weight? What
ClinicalTrials.gov NCT06918405 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT06937086
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 350. Conditions Ulcerative Colitis; Obesity or Overweight. The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body wei
ClinicalTrials.gov NCT06937086 protocol and results modules
registry, as of 2026-09-24Stale
https://clinicaltrials.gov/study/NCT06439277
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2). Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 300. Conditions Obesity; Weight Gain. The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76
ClinicalTrials.gov NCT06439277 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT06937099
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 290. Conditions Crohn's Disease; Obesity or Overweight. The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of t
ClinicalTrials.gov NCT06937099 protocol and results modules
registry, as of 2026-06-17Stale
https://clinicaltrials.gov/study/NCT06588283
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 281. Conditions Psoriasis; Obesity. The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants s
ClinicalTrials.gov NCT06588283 protocol and results modules
registry, as of 2026-05-13Stale
https://clinicaltrials.gov/study/NCT06588296
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 279. Conditions Psoriatic Arthritis; Obesity. The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement i
ClinicalTrials.gov NCT06588296 protocol and results modules
registry, as of 2024-07-16Stale
https://clinicaltrials.gov/study/NCT04844918
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 267. Conditions Obesity. The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks. Percentage of Participants Who Achieve ≥5% Body Weight Reduction 10 mg Tirzepatide 94.37 Percentage of Participants Who Achieve ≥5% Body Weight Reduction 15 mg Tirzepatide 96.05 Percentage of Participants Who Achieve ≥5% Body Weight Reduction Placebo 20.0 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 10 mg Tirzepatide 85.92 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 15 mg Tirzepatide 92.11 Percentage of Pa
ClinicalTrials.gov NCT04844918 protocol and results modules
registry, as of 2026-11-02
https://clinicaltrials.gov/study/NCT07846865
Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea. Overall status NOT_YET_RECRUITING. Phases PHASE2,PHASE3. Lead sponsor Woolcock Institute of Medical Research. Enrollment 256. Conditions Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. When used, continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnea (OSA), a condition that is mainly caused by overweight and obesity. However, CPAP is plagued by poor adherence and high rates of discontinued use leaving most patients unde
ClinicalTrials.gov NCT07846865 protocol and results modules
registry, as of 2024-01-19Stale
https://clinicaltrials.gov/study/NCT05024032
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN). Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 210. Conditions Obesity; Overweight; Metabolism and Nutrition Disorder. This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight. Percentage of Participants Who Achieve ≥5% Body Weight Reduction 10 mg Tirzepatide 91.43 Percentage of Participants Who Achieve ≥5% Body Weight Reduction 15 mg Tirzepatide 92.65 Percentage of Participants Who Achieve ≥5% Body Weight Reduction Placebo 29.41 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 10 mg Tirzepatide 70.0 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 15 mg Tirze
ClinicalTrials.gov NCT05024032 protocol and results modules
registry, as of 2026-06-29Stale
https://clinicaltrials.gov/study/NCT06075667
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 160. Conditions Obesity; Overweight. The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have com
ClinicalTrials.gov NCT06075667 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07817875
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS). Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 150. Conditions Obesity. The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in t
ClinicalTrials.gov NCT07817875 protocol and results modules
registry, as of 2026-05-27Stale
https://clinicaltrials.gov/study/NCT07284511
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar. Overall status RECRUITING. Phases PHASE2,PHASE3. Lead sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre. Enrollment 105. Conditions Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus. This research study is testing whether a weekly medication called tirzepatide can help adults with type 1 diabetes use their insulin pump more easily, specifically by reducing or eliminating the need to count carbohydrates at meals. People with type 1 diabetes must take insulin
ClinicalTrials.gov NCT07284511 protocol and results modules
registry, as of 2026-09-18Stale
https://clinicaltrials.gov/study/NCT07829198
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Universidade do Porto. Enrollment 70. Conditions Obesity. Many people who have bariatric (weight-loss) surgery do not lose as much weight as expected, or they regain weight over time. This study will test whether a medicine called tirzepatide can help these patients lose more weight and improve their overall health. Participants who ha
ClinicalTrials.gov NCT07829198 protocol and results modules
registry, as of 2026-08-03Stale
https://clinicaltrials.gov/study/NCT07738276
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Shahid Beheshti University of Medical Sciences. Enrollment 60. Conditions Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide. The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide. The main questions it aims to answer are: Does tirzepatide improve how far participants can
ClinicalTrials.gov NCT07738276 protocol and results modules
registry, as of 2026-08-04Stale
https://clinicaltrials.gov/study/NCT06162715
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2,PHASE3. Lead sponsor Vanderbilt University Medical Center. Enrollment 30. Conditions Severe Obesity; Obesity; BMI Greater Than 30. The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI \> 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirze
ClinicalTrials.gov NCT06162715 protocol and results modules
registry, as of 2026-05-06Stale
https://clinicaltrials.gov/study/NCT07298915
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor University of Virginia. Enrollment 24. Conditions Obesity & Overweight. This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with we
ClinicalTrials.gov NCT07298915 protocol and results modules
registry, as of 2026-10-07Stale
https://clinicaltrials.gov/study/NCT06143956
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 1481. Conditions Obesity; Overweight. The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entr
ClinicalTrials.gov NCT06143956 protocol and results modules
registry, as of 2026-03-23Stale
https://clinicaltrials.gov/study/NCT06037252
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 414. Conditions Type 2 Diabetes; Obesity. The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
ClinicalTrials.gov NCT06037252 protocol and results modules
registry, as of 2026-05-06Stale
https://clinicaltrials.gov/study/NCT06373146
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 392. Conditions Obesity. The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
ClinicalTrials.gov NCT06373146 protocol and results modules
registry, as of 2026-04-13Stale
https://clinicaltrials.gov/study/NCT07521631
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes. Overall status RECRUITING. Phases PHASE2. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 372. Conditions Obesity. This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzep
ClinicalTrials.gov NCT07521631 protocol and results modules
registry, as of 2026-09-29Stale
https://clinicaltrials.gov/study/NCT06603571
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 367. Conditions Obesity; Overweight. The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabet
ClinicalTrials.gov NCT06603571 protocol and results modules
registry, as of 2026-04-15Stale
https://clinicaltrials.gov/study/NCT06326060
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 354. Conditions Obesity. This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a t
ClinicalTrials.gov NCT06326060 protocol and results modules
registry, as of 2026-09-09Stale
https://clinicaltrials.gov/study/NCT06965413
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Hoffmann-La Roche. Enrollment 285. Conditions Obesity; Overweight; Overweight With One Weight Related Comorbidity. The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity,
ClinicalTrials.gov NCT06965413 protocol and results modules
registry, as of 2026-05-26Stale
https://clinicaltrials.gov/study/NCT06643728
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 252. Conditions Obesity; Overweight. The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
ClinicalTrials.gov NCT06643728 protocol and results modules
registry, as of 2026-03-27Stale
https://clinicaltrials.gov/study/NCT06732245
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Biomed Industries, Inc.. Enrollment 224. Conditions Obesity and Overweight. A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
ClinicalTrials.gov NCT06732245 protocol and results modules
registry, as of 2025-03-13Stale
https://clinicaltrials.gov/study/NCT06515418
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over. Overall status TERMINATED. Phases PHASE2. Lead sponsor BioAge Labs, Inc.. Enrollment 204. Conditions Obesity. This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety. Estimated Study Le
ClinicalTrials.gov NCT06515418 protocol and results modules
registry, as of 2026-10-30Stale
https://clinicaltrials.gov/study/NCT06700538
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Arrowhead Pharmaceuticals. Enrollment 190. Conditions Obesity. This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multipl
ClinicalTrials.gov NCT06700538 protocol and results modules
registry, as of 2025-09-17Stale
https://clinicaltrials.gov/study/NCT07179120
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor First Affiliated Hospital of Wenzhou Medical University. Enrollment 180. Conditions Obesity-related Male Infertility. Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semag
ClinicalTrials.gov NCT07179120 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07463846
A Study to Evaluate ALN-2232 in Participants With Obesity. Overall status RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Alnylam Pharmaceuticals. Enrollment 156. Conditions Obesity. The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232
ClinicalTrials.gov NCT07463846 protocol and results modules
registry, as of 2026-09-11Stale
https://clinicaltrials.gov/study/NCT05536804
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 134. Conditions Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D. We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
ClinicalTrials.gov NCT05536804 protocol and results modules